Acadian Asset Management’s Regulus Therapeutics RGLS Stock Holding History

Acadian Asset Management’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-466	Closed	–	–	1745
2023 Q4	$0	Hold	466	–	–	﹤0.01%	1798
2023 Q3	$0	Hold	466	–	–	﹤0.01%	1806
2023 Q2	$0	Hold	466	–	–	﹤0.01%	1883
2023 Q1	$0	Hold	466	–	–	﹤0.01%	1930
2022 Q4	$0	Sell	466 -7,583	-94%	-$11.9K	﹤0.01%	1893
2022 Q3	$13K	Hold	8,049	–	–	﹤0.01%	1627
2022 Q2	$17K	Buy	+8,049	New	+$19.5K	﹤0.01%	1626
2021 Q4	–	Sell	-24,619	Closed	-$170K	–	1823
2021 Q3	$170K	Sell	24,619 -35,883	-59%	-$263K	﹤0.01%	1337
2021 Q2	$492K	Buy	60,502 +13,934	+30%	+$156K	﹤0.01%	1164
2021 Q1	$726K	Buy	+46,568	New	+$689K	﹤0.01%	1061
2020 Q3	–	Sell	-1,768	Closed	-$12K	–	2323
2020 Q2	$12K	Buy	+1,768	New	+$11.6K	﹤0.01%	2161

Other funds holding RGLS

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Acadian Asset Management's RGLS Position: Q1 2024 in Review

Acadian Asset Management sold out of Regulus Therapeutics (RGLS) in Q1 2024, closing a stake of 466 shares.

Acadian Asset Management first reported a position in RGLS in Q2 2020 and held it in 11 quarters. The position peaked at $726K in Q1 2021. 45 funds tracked by Wall St. Rank hold RGLS as of Q1 2024.

Acadian Asset Management reported no remaining Regulus Therapeutics position as of Q1 2024 after selling out during the quarter.
Acadian Asset Management sold 466 Regulus Therapeutics shares in Q1 2024.
Acadian Asset Management first reported a position in Regulus Therapeutics in Q2 2020 and held it in 11 quarters.
Acadian Asset Management's Regulus Therapeutics position peaked at $726K in Q1 2021.
45 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2024.

Based on Acadian Asset Management's 13F filing for Q1 2024, filed 10 May 2024.